DGAP-News: aap: Changes in Management Board and Supervisory Board - Chairman of the Management Board / CEO Bruke Seyoum Alemu to retire early as of 30 April 2019; Rubino Di Girolamo appointed as successor as of 1 May 2019EQS
Im Artikel erwähnte Wertpapiere: aap Implantate I
DGAP-News: aap Implantate AG / Key word(s): Personnel
The Supervisory Board of aap Implantate AG ("aap") and the Chairman of the Management Board / CEO, Bruke Seyoum Alemu (54), today agreed on an early termination of his term of office as of 30 April 2019. Bruke Seyoum Alemu thereupon resigned his mandate as Member and Chairman of the Management Board / CEO of aap by mutual agreement with the Supervisory Board with effect as of 30 April 2019 and will retire from the Management Board at this time. Also today, the Supervisory Board appointed Mr. Rubino Di Girolamo (57), currently Member of the Supervisory Board at aap, as successor and new Chairman of the Management Board / CEO with effect as of 1 May 2019.
Bruke Seyoum Alemu served aap in various top management positions for many years and has been the Chairman of the Management Board / CEO since 2014. Mr. Alemu continues to be in charge of aap's operations as Chairman of the Management Board / CEO by the end of 30 April 2019. He will support the company on a consulting basis after his retirement from the Management Board. This shall ensure a smooth transition in particular with respect to the targeted market approval of the silver coating technology and the ongoing talks with global orthopaedic companies.
"Mr. Alemu decisively shaped aap in the past decades with his determination and strong leadership qualities," says Biense Visser, Chairman of the Supervisory Board at aap. "He has consistently and successfully undertaken the transformation of aap from a diversified medical technology company into a pure player in trauma. Under his leadership as co-developer and -owner of the underlying patents our comprehensive screw and plate system LOQTEQ(R) was developed which we have been successfully marketing at home and abroad since 2012. Additionally, the development of our innovative and pioneering silver coating technology significantly bears his signature. I would like to sincerely thank Mr. Alemu for this great commitment and the outstanding work in the name of the Supervisory Board, the Management Board and the entire aap staff."
Mr. Di Girolamo is currently still managing a dental technology holding in Switzerland as CEO and has been serving aap in different Supervisory Board functions for several years. Mr. Di Girolamo looks back on long-standing experience in different top management positions, inter alia, at Metalor Dental Holding AG and its affiliates, Bellevue Group and M2 Capital. He studied economics at Zürcher Hochschule für Angewandte Wissenschaften (ZHAW).
Biense Visser comments the appointment of Rubino Di Girolamo as follows: "Due to his current position Mr. Di Girolamo has many years of experience in the fields corporate management and control and a proven expertise in the medical technology industry. Additionally, he is very familiar with aap based on his different Supervisory Board activities in the past years. We are firmly convinced that with Mr. Di Girolamo and his Management Board colleague, Mr. Marek Hahn, we are well-positioned to continue to consistently develop aap into a sustainably growing pure player in trauma and to unlock the inherent value of the promising and innovative product and technology base."
In addition, the Management Board and Supervisory Board of aap resolved today to propose Ms. Dr. Natalie Krebs (47) to the competent commercial register for a judicial appointment as new Member of the Supervisory Board and successor of Mr. Di Girolamo for the period until the end of the Annual General Meeting of the company on 21 June 2019. Ms. Dr. Krebs is a graduated doctor and studied and graduated at University Basel, Switzerland. She is currently a member of the Board of Directors at several companies and has extensive experience based on different responsible positions in the pharmaceutical industry and at consulting companies.
aap Implantate AG; Fabian Franke; Investor Relations; Lorenzweg 5; D-12099 Berlin Tel.: +49/30/750 19 - 134; Fax.: +49/30/750 19 - 290; firstname.lastname@example.org
15.04.2019 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
|Company:||aap Implantate AG|
|Phone:||+49 (0) 30 75 01 90|
|Fax:||+49 (0) 30 75 01 91 11|
|Listed:||Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange|
|EQS News ID:||800075|
|End of News||DGAP News Service|